Plasmodium vivax and Mixed Infections Are Associated with Severe Malaria in Children: A Prospective Cohort Study from Papua New Guinea by Genton, Blaise et al.
Plasmodium vivax and Mixed Infections Are
Associated with Severe Malaria in Children:
A Prospective Cohort Study from Papua
New Guinea
Blaise Genton
1*¤, Vale ´rie D’Acremont
1, Lawrence Rare
2, Kay Baea
2, John C. Reeder
2, Michael P. Alpers
2, Ivo Mu ¨ller
2
1 Swiss Tropical Institute, Basel, Switzerland, 2 Papua New Guinea (PNG) Institute of Medical Research (IMR), Goroka, Papua New Guinea
Funding: The morbidity surveillance
was established as a component of
field site preparation for malaria
vaccine trials funded by grant from
USAID and AusAID. The funders had
no role in study design, data
collection and analysis, decision to
publish or preparation of the
manuscript.
Competing Interests: The authors
have declared that no competing
interests exist.
Academic Editor: Stephen
Rogerson, Royal Melbourne Hospital,
Australia
Citation: Genton B, D’Acremont V,
Rare L, Baea K, Reeder JC, et al.
(2008) Plasmodium vivax and mixed
infections are associated with severe
malaria in children: a prospective
cohort study from Papua New
Guinea. PLoS Med 5(6): e127. doi:10.
1371/journal.pmed.0050127
Received: December 7, 2007
Accepted: May 2, 2008
Published: June 17, 2008
Copyright:  2008 Genton et al. This
is an open-access article distributed
under the terms of the Creative
Commons Attribution License, which
permits unrestricted use,
distribution, and reproduction in any
medium, provided the original
author and source are credited.
Abbreviations: df, degree of
freedom; PNG, Papua New Guinea;
SM, severe malaria; SP, sulfadoxine-
pyrimethamine; UM, uncomplicated
malaria; WBC, white blood cells
* To whom correspondence should
be addressed. E-mail: Blaise.
Genton@unibas.ch
¤ Current address: Ifakara Health
Research and Development Center,
Dar Es Salaam, United Republic of
Tanzania
ABSTRACT
Background
Severe malaria (SM) is classically associated with Plasmodium falciparum infection. Little
information is available on the contribution of P. vivax to severe disease. There are some
epidemiological indications that P. vivax or mixed infections protect against complications and
deaths. A large morbidity surveillance conducted in an area where the four species coexist
allowed us to estimate rates of SM among patients infected with one or several species.
Methods and Findings
This was a prospective cohort study conducted within the framework of the Malaria Vaccine
Epidemiology and Evaluation Project. All presumptive malaria cases presenting at two rural
health facilities over an 8-y period were investigated with history taking, clinical examination,
and laboratory assessment. Case definition of SM was based on the World Health Organization
(WHO) criteria adapted for the setting (i.e., clinical diagnosis of malaria associated with asexual
blood stage parasitaemia and recent history of fits, or coma, or respiratory distress, or anaemia
[haemoglobin , 5 g/dl]). Out of 17,201 presumptive malaria cases, 9,537 (55%) had a
confirmed Plasmodium parasitaemia. Among those, 6.2% (95% confidence interval [CI] 5.7%–
6.8%) fulfilled the case definition of SM, most of them in children ,5 y. In this age group, the
proportion of SM was 11.7% (10.4%–13.2%) for P. falciparum, 8.8% (7.1%–10.7%) for P. vivax,
and 17.3% (11.7%–24.2%) for mixed P. falciparum and P. vivax infections. P. vivax SM presented
more often with respiratory distress than did P. falciparum (60% versus 41%, p¼0.002), but less
often with anaemia (19% versus 41%, p ¼ 0.0001).
Conclusion
P. vivax monoinfections as well as mixed Plasmodium infections are associated with SM.
There is no indication that mixed infections protected against SM. Interventions targeted
toward P. falciparum only might be insufficient to eliminate the overall malaria burden, and
especially severe disease, in areas where P. falciparum and P. vivax coexist.
The Editors’ Summary of this article follows the references.
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Most of the research and published literature on malaria
focuses on P. falciparum and much less on P. vivax [1,2]. This
focus is due to the very high burden of mortality attributed to
the falciparum species in Africa [3]. However, there is growing
evidence that P. vivax is responsible for a signiﬁcant burden
of disease worldwide accounting for half of all malaria cases
in Asia and Latin America [4]. As the term ‘‘benign tertian
malaria’’ implies, vivax malaria is usually an uncomplicated
disease that runs a benign course and is rarely fatal. This
clinical paradigm has been challenged recently [5] by
numerous reports of symptoms and signs of severe disease,
and even deaths due to P. vivax monoinfections [6–9].
However, most of the published literature consists of case
reports or small descriptive clinical series lacking denomi-
nators. The relative contribution of P. vivax versus P.
falciparum to severe morbidity has not been properly assessed,
except for one study in Thailand that found very little severe
disease and no death due to P. vivax [10]. This Thai study
suggested, rather, a protecting effect of vivax, as had a study
from Vanuatu [11,12]. It is only recently that severe disease
due to P. vivax has received more attention with a recent
report from a hospital in northeastern Indonesian New
Guinea (Papua) where they found 36 severe malaria (SM)
cases among 1,135 P. vivax infected patients (3.2%) [13].
The malaria epidemiology in Papua New Guinea (PNG)
offers the opportunity to investigate in the same population
t h er e s p e c t i v ec o n t r i b u t i o no ft h ed i f f e r e n tPlasmodium
species in terms of morbidity, and severe disease in
particular. Indeed, it is one of the few countries where all
four Plasmodium species coexist at sufﬁcient prevalence to
allow proper comparisons. The aim of the present clinico-
epidemiological study was to assess the proportion of cases
presenting at health facilities with severe manifestations of
malaria and associated P. vivax parasitaemia, to compare this
proportion to that of P. falciparum in the same setting, and to
investigate the potential of mixed P. falciparum and P. vivax
infection to protect against severe disease.
Methods
Study Area and Population
The Wosera lies in the East Sepik Province of PNG.
Transmission of malaria is perennial, but the distribution of
rainfall shows some seasonality with 65% falling during the
so-called wet season occurring from October to April.
Malariometric surveys conducted in the area showed an
overall Plasmodium prevalence rate of 60% in the early 1990s
decreasing to 35% by 2002. The reduction was from 38% to
22% for P. falciparum, 20% to 10% for P. vivax, 16% to 4% for
P. malariae [14,15], and was probably related to a gradual
increase in the use of insecticide treated nets and a change in
treatment policy.
Health Services
The morbidity surveillance was conducted in two health
facilities, Kunjigini Health Subcentre in the South Wosera
and Kaugia Health Subcentre in the North Wosera, within the
framework of the Malaria Vaccine Epidemiology and Evalua-
tion Project [16]. Both health facilities are staffed with nurses
and have beds to admit severe cases for a short period of time.
Limited laboratory tests are available (light microscopy for
malaria, haemoglobin photometer, and urine dipstick). The
local referral centre is Maprik Hospital, a 110-bed govern-
ment hospital. Recourse to health services is usual in case of
fever, especially in children, but referral is very uncommon,
due to transport problems and lack of qualiﬁed staff in the
hospital. First-line treatment policy for uncomplicated
malaria (UM) was a 3-d regimen of oral amodiaquine in
children , 20 kg, or chloroquine in those . 20 kg; treatment
for severe or resistant malaria included a 5-d regimen of
intramuscular quinine combined with a single dose of oral
sulfadoxine-pyrimethamine (SP). In 2000, the ﬁrst-line treat-
ment changed to a combination of amodiaquine or chlor-
oquine (3 d) plus SP (single dose) for UM, and the second-line
to artesunate (7 d) plus SP (single dose on day 3). The 28-d
failure rates with the regimens used in the area during the
study were ;20% for P. falciparum and ;0% for P. vivax
[17,18].
Morbidity Surveillance
Patients were prospectively recruited if they were diag-
nosed on clinical grounds only as having malaria (presump-
tive diagnosis). The diagnosis was based on a history of fever
without obvious symptoms or signs of another disease. These
presumptive malaria cases were further investigated by a
research nurse. After recording demographical information,
closed questions were asked on the characteristics of the
morbid episode (history of fever, headache, cough, dyspnea,
vomiting, diarrhoea, abdominal pain, and convulsions). A
standardized physical examination was then performed
(axillary temperature, level of consciousness, respiratory rate,
chest indrawing, and Hackett’s grading of spleen). A blood
sample was taken for parasitological examination by micro-
scopy and haemoglobin measurement (for details see Genton
et al. [19]).
Laboratory Tests
Parasitology. Blood ﬁlms were stained with 4% Giemsa and
examined for 100 microscopic thick ﬁlm ﬁelds prior to being
declared negative. In positive ﬁlms, parasite species were
identiﬁed and densities were recorded as the number of
parasites per 200 white blood cells (WBC). This procedure was
followed for each species. Densities were converted to
parasites per microliter of blood, assuming 8,000 WBC per
microliter. A routine quality control procedure was per-
formed [20]. Brieﬂy, 10% of randomly selected slides and all
those that had a density between 1 and 5 parasites per 200
WBC (for any of the four species) were reread, in a blinded
fashion, by a supervisor microscopist. When the results on a
batch of ;1,000 slides did not reach 75% agreement on
positivity/negativity, species, and density (including a margin
of error that increased with increasing density), the entire
batch was reread and the same quality control applied again.
Haemoglobin concentration. Haemoglobin level was deter-
mined using the HemoCue photometer (A ¨ ngelholm).
Ethical approval and informed consent
The morbidity surveillance in the Wosera area received
ethical approval from the Medical Research Advisory
Committee (MRAC) within the framework of the larger
Malaria Vaccine Epidemiology and Evaluation Project [16].
Patients or patients’ guardians were asked for oral informed
consent by the research nurse. This mode of consent was
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setting where many people cannot read and write. Moreover,
the procedures performed (systematic history taking, clinical
examination, and diagnostic test for malaria) provided
patients with a laboratory-conﬁrmed diagnosis of malaria
and consequently with better management of the illness.
Data Analysis
Case deﬁnitions. A UM case was deﬁned as a presumptive
malaria patient (see above) associated with documented
Plasmodium asexual blood-stage parasitaemia by light micro-
scopy.
A SM case was deﬁned using the standard criteria
established by the World Health Organization (WHO), except
that we also included species other than P. falciparum, and we
did not take into account a parasite density .250,000/ll since
we expected lower densities in P. vivax than in P. falciparum
infections [21]. Because clinical and laboratory facilities were
limited in the setting we were working in, we could only assess
a subset of criteria deﬁning SM. Thus, our deﬁnition included
a patient with presumptive malaria associated with docu-
mented Plasmodium asexual blood-stage parasitaemia, and
with at least one of the following: history of more than one
convulsion in the last 24 h; coma (patient unable to localize a
painful stimulus); respiratory distress (high respiratory rate
[. 50 for children 0 to , 2 mo of age and . 40 for others
including adults] and chest indrawing or shortness of breath);
and haemoglobin , 5 g/dl. Since there is ongoing debate
about whether it is appropriate or not to include patients
with associated symptoms or signs (comorbidity), we also
report on a more restricted deﬁnition excluding patients with
associated cough and/or diarrhoea, two features that may or
may not be related to malaria [22]. The latter symptoms were
usually mild since, if signiﬁcant, the patients would not have
been diagnosed as presumptive malaria.
Analysis. We analysed the proportion of SM cases by
species (P. falciparum monoinfection, P. vivax monoinfection,
and mixed P. falciparum and P. vivax infections) among all
malaria cases (UM and SM) recorded in the morbidity
surveillance from 1997 to 2004. We stratiﬁed our analysis by
age group, since we expected different effects in individuals
with different level of pre-existing immunity. We focused
most of the analyses in the 0- to 5-y age group, since in highly
endemic areas of PNG vivax malaria and SM, in particular, are
encountered mainly in young children [23,24].
The chi square test was used (i) to compare rates of SM
between the groups of malaria cases infected with P.
falciparum, P. vivax, or mixed species; (ii) to investigate
seasonal variation of SM rates; and (iii) to compare the
distribution of clinical and laboratory features deﬁning SM
between groups of SM patients infected with P. falciparum, P.
vivax, or mixed species. The proportions of cases with each of
these features among P. falciparum, P. vivax, or mixed species
SM are illustrated by Venn diagrams (created using free
software that draws three set area proportional graphs) [25].
A chi square for trend was used to investigate the pattern of
SM over the 8-y period.
Parasite densities were compared between severe and
uncomplicated malaria as well as between species using log-
transformed data and t-tests.
Data management was performed using the Foxpro
software and data analysis Stata version 6. Since only a
subsample of our patients in the morbidity surveillance were
also included in the demography surveillance database
(different villages), no systematic follow-up was possible.
Results
A total of 73,620 patients were registered in the 8-y period
of the morbidity surveillance from 1997 to 2004. Among
those, 17,201 cases were diagnosed as presumptive malaria
cases and investigated further by the research nurse. A total
of 9,537 of those patients (55%) had asexual Plasmodium
parasitaemia. Among those, 6,886 (72%) had pure P.
falciparum, 1,946 (20%) P. vivax, 328 (3%) P. malariae,2 7
(0.3%) P. ovale, and 350 (4%) mixed infections (314 P.
falciparum and P. vivax;2 1P. falciparum and P. malariae; ten P.
vivax and P. malariae; three P. falciparum and P. ovale; one P.
malariae and P. ovale; and one P. falciparum, P. vivax, and P.
malariae). The age-speciﬁc parasite prevalence and species
distribution among all presumptive malaria cases is shown in
Figure 1. The highest parasite prevalence was found in
children aged 5 to , 10 y (peak age 7 y). On the other hand,
the highest proportion of P. vivax was seen in children 2 to ,
5 y (peak age 2 y), with up to 20% parasitaemic.
Among parasitaemic individuals with all data available
(7,759), 6.2% (95% conﬁdence interval [CI] 5.7%–6.8%)
fulﬁlled the case deﬁnition of SM. Table 1 details the
proportion of SM cases associated with P. falciparum, P. vivax,
and mixed P. falciparum and P. vivax infections by age group
using two different case deﬁnitions: standard and restricted
(excluding patients with cough or diarrhoea). Children aged
, 2 y were more likely to have SM (standard deﬁnition) than
those aged 2 to , 5 y (odds ratio [OR] 2.2, 95% CI 1.8–2.7)
and those aged 5 to , 10 y (OR 6.4, 95% CI 4.7–8.6); for
individuals infected with P. vivax, the ORs were of 2.8 (95% CI
1.8–4.4) and 7.5 (95% CI 3.5–15.7), respectively; for individ-
uals infected with P. falciparum, the ORs were of 2.0 (95% CI
1.5–2.6) and 6.0 (95% CI 4.2–8.5); for individuals with mixed
infections, the ORs were of 3.2 (95% 95% CI 1.3–8.0) and 32.1
(95% 95% CI 3.2–319, Fisher’s exact , 0.001). The decrease in
risk of severe disease was linear with age for all patients with
P. falciparum, P. vivax, or mixed infections (Figure 2). The
decrease in risk was signiﬁcantly more pronounced for mixed
(OR 0.52/y, CI 0.38–0.72) compared to single infections (OR
0.72/y, 95% CI 0.68–0.76, likelihood ratio [LR] v
2¼4.7, degree
of freedom [df]¼1, p¼0.03), but similar for P. falciparum (OR
Figure 1. Age-Specific Prevalence of Parasitaemia among Presumptive
Malaria Cases
doi:10.1371/journal.pmed.0050127.g001
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Severe vivax Malaria0.73/y, 95% CI 0.68–0.74) and P. vivax single infections (OR
0.65/y, CI 0.56–0.77, likelihood ratio [LR] v
2 ¼ 2.5, df ¼ 1, p ¼
0.11).
Figure 3 shows the proportion of SM in children , 5y
infected with any species (except P. ovale because cases were
too few) or mixed infections. Children , 5 y infected with
both P. falciparum and P. vivax infections (mixed) were more
likely to present with SM than those who were infected with P.
falciparum only (17% versus 12%, OR 1.5, 95% CI 1.0–2.4), or
P. vivax only (17% versus 9%, respectively, OR 2.1, 95% CI
1.3–3.5). In children , 2 y, almost one-third (29%) with mixed
infections had SM. In this age group, the proportion of SM
among P. vivax infections was close to that among P. falciparum
infections (14% versus 18%, respectively, for the standard
deﬁnition, 4% versus 6% for the restricted deﬁnition) (see
Table 1).
The proportion of SM cases (, 5 y) presenting with each
type of clinical manifestation or laboratory feature deﬁning
SM is shown schematically in Figure 4 by Venn diagrams for
the group of SM infected with P. vivax, P. falciparum, or mixed
species. P. vivax SM and mixed SM presented more often with
respiratory distress than did P. falciparum SM (61% versus
41%, v
2 ¼ 9.85, p ¼ 0.002 and 67% versus 41%, v
2 ¼ 5.88, p ¼
0.015, respectively), but less often with anaemia; the latter
being only signiﬁcant for the comparison between P. vivax
and P. falciparum (19% versus 41%, v
2¼14.57, p¼0.0001 and
29% versus 41%, v
2 ¼ 1.36, p ¼ 0.2). Neurological manifes-
tations tended to be less frequent in mixed SM than in P.
falciparum or P. vivax SM (8% versus 23% and 26%,
respectively), but none of the differences were signiﬁcant,
probably due to the small numbers. Comparing the rate of
each neurological sign between P. vivax and P. falciparum SM,
ﬁts were as frequent in both species (22% for both, v
2¼0, p¼
0.96); as well as coma (4% versus 2%, respectively, v
2¼1.25, p
¼ 0.26).
More generally, among all children , 5 y with parasitaemia,
the prevalence of anaemia was 5.1% in patients infected with
P. falciparum, 1.6% in those with P. vivax, and 5.3% in those
with mixed infections; respiratory distress was found in 5.5%
of P. falciparum patients, 5.1% of P. vivax patients, and 10.3%
of those with mixed infections; and repeated convulsions
were encountered in 2.5% and coma in 0.2% of P. falciparum
patients, in 2% and 0.3%, respectively, of P. vivax individuals,
and in 1.1% and 0%, respectively, of those with mixed
infections.
To investigate whether the increased risk of SM in children
infected with two species was due to a higher overall parasite
burden, we compared densities in mixed infections versus
those in monoinfections. As shown in Figure 5 (restricted to
children , 5 y), total parasite densities were indeed
signiﬁcantly higher in children with mixed infections than
in those with P. falciparum or P. vivax monoinfections, whether
all cases (t ¼  2.41, df ¼ 2,968, p ¼ 0.02 and t ¼  11.57, df ¼
1,372, p , 0.01, respectively) or the severe ones only (t¼ 2.38,
df ¼ 283, p ¼ 0.02 and t ¼  5.39, df ¼ 108, p , 0.01,
respectively) were considered. Densities tended to be lower in
the severe P. falciparum and P. vivax cases than in the
uncomplicated ones; the reverse was true in cases with mixed
infections. In the latter, the average proportion of P.
falciparum density/total parasite density was 83% in the UM
and 87% in SM.
Age was the prominent risk factor for presenting with SM,
but the season and year of attendance also had a signiﬁcant
effect. Malaria (parasitaemic) patients attending during the
wet season were more likely to have SM than those attending
during the dry season (OR 1.3, 95% CI 1.1–1.6), and this effect
was signiﬁcant for P. vivax (OR 1.9, 95% CI 1.2–2.9), but not
for P. falciparum (OR 1.1, 95% CI 0.9–1.4), or mixed infections
(OR 0.8, 0.4–1.9). Over the years, there was a signiﬁcant
decrease in the rate of SM (OR 0.8, 95% CI 0.7–0.8), with a
clear step observed from 2000 onward, probably as a
consequence of the new treatment policy that was introduced
in that year (adding SP to amodiaquine or chloroquine).
Discussion
The present study shows that in a rural area of PNG where
all four species of Plasmodium coexist, P. vivax is responsible
for 21% of all SM cases, P. falciparum for 71%, and mixed P.
vivax and P. falciparum infections for 5%. A feature of this
clinico-epidemiological report is the simultaneous presence
of P. falciparum as an internal control for P. vivax, so that the
relative proportions of severe disease can be determined,
regardless of its deﬁnition. The proportion of patients , 5y
Figure 2. Age-Specific Risk of Severe Disease with P. falciparum, P. vivax,
and Mixed Infections in Children ,10 y
doi:10.1371/journal.pmed.0050127.g002
Figure 3. Mosaic Plot of SM by Species in Children , 5y
Horizontal, species; vertical, proportion of SM.
doi:10.1371/journal.pmed.0050127.g003
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was as high as 9%. The corresponding value for P. falciparum
was 12%. Since the evaluators and the deﬁning criteria for
uncomplicated and severe malaria were strictly the same, we
can be conﬁdent that the relative values (P. vivax versus P.
falciparum) are correct. Moreover, the absolute value for the
proportion of severe cases among all P. falciparum-infected
children (12%) was lower than those found in numerous
other studies of clinical malaria, the main reason being that
our study took place in a peripheral health facility and not in
a referral hospital as most, if not all, other studies [26–28]. It
is clear that this absolute value depends entirely on the
criteria used to deﬁne SM and on the population from which
the cases are selected. Since we were working in a setting that
did not allow us to measure certain parameters included in
the WHO deﬁnition, such as glycemia or creatininemia, we
probably slightly underestimated the true proportion of
severe malaria caused by both species. Whichever deﬁnition is
used, the relative contribution of P. vivax to the overall
burden of SM morbidity is considerable in this region, and
especially in children ,2 y, where the proportion of P. vivax
parasitaemic children presenting with severe disease reached
a worrying rate of 14% (versus 18% for P. falciparum). These
data on severe vivax malaria are in line with those reported in
a joint paper from a hospital in Papua, Indonesia, also
published in this issue of the journal [28]. In that setting,
severe disease was present in 23% of the patients with
malaria, with rates similar for P. falciparum and P. vivax (22%),
but signiﬁcantly higher in patients with mixed infections
(34%). These two observational studies, although both
originating from the same region of the world, add to the
growing realization that P. vivax is not benign. They are the
ﬁrst studies, to our knowledge, to incorporate denominators
that allow assessing the relative magnitude of the problem
when compared to that of P. falciparum.
Although all types of malaria complications observed with
P. falciparum were also encountered with P. vivax, their
distribution was different: severe cases of P. vivax were less
likely than those of P. falciparum to present with anaemia, but
more likely to suffer from respiratory distress. These
observations are understandable since we know that P. vivax
malaria patients have lower densities than P. falciparum
patients, and therefore the likelihood of having profound
anaemia is less, even if other immunological factors may
contribute to red cell destruction. The proportion of severe
P. vivax cases with anaemia was much less in our study (19%)
than in Tjitra’s (86%) [28]. Their hypothesis of P. vivax
resistance contributing largely to the high prevalence of
anaemia in their setting is plausible since we had 0% P. vivax
resistance in the Wosera during the study period [17,18]
versus 65%–95% in theirs [29,30]. Our ﬁnding of increased
risk of respiratory distress in vivax patients when compared to
falciparum patients is in line with recent data from Anstey et
al. who showed a more severe alveolar-capillary dysfunction
in vivax than falciparum malaria [31]. These observations are
consistent with a greater inﬂammatory response to a given
parasite burden in P. vivax relative to that in P. falciparum, and
suggest that P. vivax infected erythrocytes may sequester
within the pulmonary microvasculature [31]. Severe vivax
malaria is thus an emerging recognized entity, and the long-
standing belief that P. vivax is a nonsequestering parasite
might need to be revisited [31,32].
Contrary to the study in Thailand that reported lower
frequencies of SM in dual P. vivax and P. falciparum infections
[10,33], we found that patients with mixed infections were
more likely to present with SM than those infected with a
single Plasmodium species. Our data are in line with case series
from India [34], Malaysia [35], and Indonesia [28]. The
mechanism for the higher proportion of SM among patients
with mixed infections might be a higher overall parasite load.
Indeed we found that severe cases with mixed infections had
higher parasite densities than those with single P. falciparum
and, even more so, P. vivax infection. This increased severity
does not formally contradict the possible protective role of
asymptomatic P. vivax infection against a subsequent P.
falciparum morbid episode. In a study conducted in the same
Figure 4. Proportion of SM Cases with Each of the Main Defining Clinical
or Laboratory Features among Children ,5 y Infected with P. vivax, P.
falciparum, and Mixed Species (Venn Diagram)
doi:10.1371/journal.pmed.0050127.g004
Figure 5. Total Parasite Densities in Uncomplicated and SM by Species
(Children ,5y )
Line is median, boxes are 25th and 75th percentile, and whiskers are
upper and lower adjacent values.
doi:10.1371/journal.pmed.0050127.g005
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infected with P. vivax, P. malariae, or mixed infections were
less likely to have a morbid episode with P. falciparum during
follow-up. This may mean that indeed non-falciparum species
could protect against the risk of morbid episode because of P.
falciparum, but, once the disease is established, having mixed
infection makes the patient sicker, owing to the higher
parasite density, as found in our study. This hypothesis must
be balanced against the observation that, also in our series,
SM cases with single P. falciparum or P. vivax infection did not
harbor higher parasite densities than uncomplicated cases.
This has been repeatedly found in different settings. Parasite
density has not been identiﬁed as a risk factor for death in
one of the largest series of malaria cases in Africa [37].
Our study is limited by the fact that parasite species were
identiﬁed by microscopy, and it is known that this method
largely misses minority infections [15,38,39]. Thus, mixed
infections may have been largely underestimated, and a more
sensitive detection method may have led to different results.
While this limitation may be valid, it is believed that, in
general, the infections that make the patient sick are those of
high density, and that these are the ones that are identiﬁed by
microscopy, as in the present study; those with very low
densities are unlikely to contribute much to the acute phase,
and even less to severe manifestations.
Another potential limitation is the accuracy of malaria
diagnosis. In a high transmission area, where the prior
probability of a young child being parasitaemic is high, the
diagnosis of clinical malaria is not straightforward. We know
from comparable settings in Africa that sepsis is commonly
misdiagnosed as malaria, or that pneumonia can be associ-
ated with malaria. Since no blood cultures and no chest
radiographs were performed, we cannot be certain that these
children did not have a disease other than malaria. However,
this potential bias is inherent to all studies of SM, even those
that include thorough clinical assessment and sophisticated
laboratory procedures. In intervention studies, a parasite
density threshold is advised to increase the speciﬁcity of the
diagnosis. When using a P. falciparum density threshold that
should have led to over 90% sensitivity and 90% speciﬁcity
for a diagnosis of malaria in this area and age group (, 5y )
[40], we found that 74% of the P. falciparum UM and 71% of
the P. falciparum SM were above 4,000 parasites/ll. When
applying the same statistical methodology to P. vivax (I.
Mueller, personal correspondence), 71% of the P. vivax UM
and 66% of the P. vivax SM were above 1,000 parasites per
microlitre. We can thus postulate that at least two-thirds of
the cases were ‘‘true’’ malaria. Even if some of our cases
actually had alternative/additional diagnoses, the ﬁnding of
severe disease with an associated P. vivax parasitaemia cannot
be disregarded, as in P. falciparum cases [41]. These children
should still be managed as SM cases, whether illness is due to
P. falciparum,t oP. vivax, or to another cause indistinguishable
from malaria [42,43]. This approach is supported by a recent
retrospective analyses of hospital records in Jayapura, West
Papua, Indonesia, which found risk of fatal outcomes among
SM patients was comparable between those with falciparum
versus vivax malaria [13]. Epidemiological studies such as the
present one should be used as a notice for clinicians working
in areas where P. vivax is present, and as a signal for
researchers to further investigate the pathogenesis of P. vivax
malaria and the potential associated comorbidities, such as
sepsis, in the same way as has been done for P. falciparum [44].
Why is P. vivax malaria only now recognized as a potential
serious threat to life, although the parasite has been present
for centuries? One of the reasons may be that SM has always
been, and almost exclusively, associated with cerebral
complications, and the latter are rare in P. vivax. The
prejudice to only consider P. falciparum as potentially severe
was therefore difﬁcult to overcome. It is only in the 1990s that
other clinical manifestations and laboratory parameters have
been identiﬁed as indicators of poor outcome [26]. Anaemia
and respiratory distress, for example, have been recently
included in the case deﬁnition of SM, and these signs are
encountered frequently in P. vivax malaria. There is therefore
increased awareness to recognize manifestations that may be
less apparent than coma, but still harbor poor prognosis.
Also, the relatively recent establishment of large morbidity
surveillance systems in different epidemiological settings has
improved the ability of researchers to capture unexpected
events or trends.
The ﬁnding that a signiﬁcant proportion of SM morbidity
is due to P. vivax calls for interventions that do not target P.
falciparum parasites only, at least in areas where several
Plasmodium species coexist. In areas with multiple species, new
interventions should be assessed for their effectiveness on
overall malaria morbidity, so that potential interactions,
especially compensatory effects on other species, can be
identiﬁed early enough, before widespread implementation.
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Background. Malaria is a parasitic infection that is transmitted to people
by infected mosquitoes. Four different parasites cause malaria—
Plasmodium falciparum, P. vivax, P. ovale, and P. malariae. Of these, P.
vivax is the commonest and most widely distributed, whereas P.
falciparum causes the most deaths. All these parasites enter their human
host when an infected mosquito takes a blood meal. They then migrate
to the liver where they replicate without causing any symptoms. Eight to
nine days later, mature parasites are released from the liver cells and
invade red blood cells. Here, they multiply rapidly before bursting out
and infecting more red blood cells. The recurring flu-like symptoms of
malaria are caused by this cyclical increase in parasitemia (parasites in
the blood) and should be treated promptly with antimalarial drugs to
prevent the development of potentially fatal complications. Infections
with P. falciparum in particular can cause anemia by destroying the red
blood cells and can damage vital organs (including the brain) by
blocking the capillaries that supply them with blood.
Why Was This Study Done? It is generally believed that P. vivax malaria
is rarely fatal. There is even some evidence that infection with P. vivax
alone (monoinfection) or with other malaria parasites (mixed infection)
provides protection against malarial complications. Recently, however,
there have been reports of severe disease and deaths associated with
infection by P. vivax alone. Most of these reports do not indicate what
proportion of severe malaria cases are caused by P. vivax infections, but if
P. vivax is responsible for a significant proportion of malarial deaths,
efforts to prevent these deaths will need to target P. vivax as well as P.
falciparum. In this study, therefore, the researchers estimate the
proportion of cases of severe malaria among patients infected with
one or several Plasmodium species in Papua New Guinea, a country
where all four species coexist.
What Did the Researchers Do and Find? The researchers enrolled
everyone attending two rural health facilities in the Wosera subdistrict of
Papua New Guinea over an eight-year period with symptoms indicative
of malaria but without symptoms of any other disease (presumptive
malaria cases) into their prospective cohort study. They asked each
patient about their symptoms, did a standard physical examination,
looked for parasites in their blood, and measured their hemoglobin
levels to see whether they were anemic. Out of 17,201 presumptive
malaria cases, 483 had severe malaria (defined as parasitemia plus a
recent history of fits, coma, breathing problems, or anemia). Most of the
patients with severe malaria were less than five years old—children have
little immunity to Plasmodium parasites. In this age group, 11.7% of
patients infected with P. falciparum, 8.8% of patients infected with P.
vivax, and 17.3% of patients infected with both parasites had severe
malaria. Patients with severe malaria caused by P. vivax presented with
breathing difficulties more often than those infected with P. falciparum,
whereas anemia was more common among patients with severe malaria
caused by P. falciparum than by P. vivax.
What Do These Findings Mean? The researchers use these results and
data on the numbers of infections with each parasite to calculate that, in
this rural region of Papua New Guinea, P. vivax is responsible for one-fifth
of severe malaria cases, P. falciparum is responsible for three-quarters of
cases, and the rest involve mixed P. falciparum/P. vivax infections. Put
another way, these findings suggest that about one in ten children under
the age of five years infected with either P. vivax or P. falciparum may
develop severe malaria. These findings provide no evidence, however,
that mixed infections are protective. Because the diagnosis of severe
malaria was not confirmed by outcome data (deaths or permanent
disability), additional, more detailed studies are needed to confirm these
results. Nevertheless, these findings (and those reported separately in a
related article published at the same time in PLoS Medicine) suggest that
a significant proportion of the illness associated with malaria may be
caused by P. vivax infections. Thus, efforts to reduce or eliminate the
malarial burden must target P. vivax as well as P. falciparum in regions
where these species coexist.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050127.
  A PLoS Medicine Research in Translation article by Stephen Rogerson
further discusses this study and a related paper on vivax malaria
infection in patients attending a regional hospital in Papua, Indonesia
  The MedlinePlus encyclopedia has a page on malaria (in English and
Spanish)
  The US Centers for Disease Control and Prevention provides
information on malaria (in English and Spanish)
  Information is available from the Roll Back Malaria Partnership on
global control of malaria and on malaria in Papua New Guinea
  Vivaxmalaria provides information for the malaria research community
on topics related to Plasmodium vivax
  The Malaria Vaccine Initiative also provides a fact sheet on Plasmodium
vivax malaria
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